On February 10, 2020, the White House released the
Administration’s budget proposal for Fiscal Year (FY) 2021, A
Budget For America’s Future. This document summarizes the President’s
recommendations
On January 28, 2020, HRSA posted results
of its 340B Program audit of four pharmaceutical manufacturers in fiscal year 2019. Three of the four
audited manufacturers were
On January
27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight
by the Department of Health and Human Services (HHS) of
On January
10, 2020, the U.S. Government Accountability Office (GAO) released a report
(the Report) analyzing HRSA’s oversight of 340B eligibility requirements for
nongovernmental hospitals. The Report concludes
HRSA announced that it has awarded Apexus LLC the prime vendor contract again after a competitive bid process. Apexus has been the 340B Prime Vendor
Last week, Apexus published a tool which states for the first time HRSA’s policy that all non-FQHC federal grantees are required to register each of
On October 9, 2019, the White House issued two executive orders with potential implications on HRSA’s ability to enforce its sub-regulatory guidance, including its patient
340B Health reports that Capt. Krista Pedley, the Director of OPA, stated last week at the Medicaid Drug Rebate Conference that OPA is reevaluating its
The Centers for Disease Control and Prevention (CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC) has scheduled a public meeting
In June 2018, Genesis Health Care, Inc., an FQHC in South Carolina, filed a lawsuit challenging its removal from the 340B program. HRSA removed Genesis
